An interventional study of Personalized optimal gamma auditory frequency stimulation and Non-optimal gamma auditory frequency stimulation in Gamma Oscillations, Healthy Adults and Alzheimer's Disease (AD), sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital — 6 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Chang Gung Memorial Hospital.
Among the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital, this one is the 25th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 27th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →6 of the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 60+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 50–90
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18+
Chang Gung Memorial Hospital
Men only · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11
First in 2009; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 67 across the 25 interventional studies, 431 across the 2 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
4 of the studies in Alzheimer Disease by Chang Gung Memorial Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06467539Chang Gung Memorial HospitalNovel Augmentation of DAOIB and Antioxidant for Early Dementia | 2027-05 |
| NCT07458620Chang Gung Memorial HospitalProspective Single-Arm Safety Study of Cervical LVA in AD Patients | 2027-05 |
| NCT06519643Chang Gung Memorial HospitalBuilding Your Successful Nursing Career | 2027-08-01 |
| NCT07690865Chang Gung Memorial HospitalInvestigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate whether personalized gamma-frequency auditory stimulation enhances cognitive function and brain synchronization. While 40 Hz auditory stimulation has been widely studied, recent evidence suggests optimal frequencies vary by individual. Using a cross-over design with 20 healthy adults, the research compares "optimal" versus "non-optimal" frequencies over one-month intervention periods. Effectiveness is measured through EEG recordings and executive function tasks. The goal is to determine if personalized sensory intervention provides a more effective, non-invasive strategy for enhancing cognitive performance.
Previous studies have shown that 40-Hz gamma-band sensory stimulation can reduce Aβ and p-tau burden and improve memory performance in AD mouse models. However, findings from human studies remain inconsistent due to differences in intervention duration and stimulation protocols. Recent studies further suggest that the optimal frequency for inducing gamma-band neural entrainment varies across individuals. In addition, a pilot study conducted in our laboratory found that the optimal auditory stimulation frequency was not necessarily 40 Hz for all participants. Therefore, the present study aims to investigate the effects of optimal auditory frequency stimulation on cognitive performance and its relationship with electrophysiological changes measured by EEG.
The study will recruit 20 cognitively healthy adults. Participants who are willing to join the study will first undergo a screening session to determine whether they meet the inclusion and exclusion criteria and whether auditory stimulation can induce significant neural entrainment. Those who meet the eligibility criteria will proceed to the intervention stage.
This study will adopt a crossover design. All participants will receive two stages of auditory stimulation intervention. Prior to the intervention, participants will be randomly assigned in a 1:1 ratio to one of two experimental groups. One group will receive optimal auditory frequency stimulation during the first stage, while the other group will receive non-optimal auditory frequency stimulation (i.e., the frequency producing the weakest neural entrainment effect). Each group will include 10 participants. During the second intervention stage, the two groups will switch experimental conditions (optimal/non-optimal auditory frequency stimulation).
Each stage will last for one month, with stimulation lasts five days per week and one hour per day. After each intervention session, participants will complete an experimental log form to record adverse effects. A one-month washout period will be implemented between the two intervention stages.
EEG recordings will be conducted before and after each intervention stage, including resting-state EEG, optimal auditory stimulation EEG recordings, and cognitive tasks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient receives personalized optimal gamma auditory frequency stimulation at home for 1 month, 5 days per week, and 1 hour per day. The stimulation frequency is selected based on the frequency that produces the strongest neural entrainment.
Device: Personalized optimal gamma auditory frequency stimulation
The patient receives non-optimal gamma auditory frequency stimulation at home for 1 month, 5 days per week, and 1 hour per day. The stimulation frequency is selected based on the frequency that produces the weakest neural entrainment.
Device: Non-optimal gamma auditory frequency stimulation
Participants will receive personalized optimal gamma auditory frequency stimulation using our app downloaded in the mobile device to play the sound for 1 hour per day, 5 days a week, over 1 month.
Participants will receive non-optimal gamma auditory frequency stimulation using our app downloaded in the mobile device to play the sound for 1 hour per day, 5 days a week, over 1 month.
changes in neurophysiological function
EEG oscillation within the gamma band obtained during resting-state and the periods of optimal and non-optimal auditory stimulation will be analyzed to evaluate and compare the neurophysiological changes.
Time frame: Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
changes in working memory performance
Behavioral performance and electrophysiological activity will be evaluated via a working memory task.
Time frame: Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
changes in inhibitory control performance
Behavioral performance and electrophysiological activity will be evaluated via an inhibitory control task.
Time frame: Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 13 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital →